Search the Newsreel

DiaMedica Therapeutics (DMAC) CEO receives 60,200 RSU award vesting over four years

DiaMedica Therapeutics Inc.'s President & CEO, Dietrich John Pauls, was granted 60,200 restricted stock units (RSUs). These RSUs will vest in four equal annual installments, contingent on his continued service. Following this award, Pauls beneficially holds 128,791 voting common shares, including deferred share units.

DiaMedica Therapeutics Inc (DMAC) Earnings Forecast: Future EPS & Revenue Growth Estimates

DiaMedica Therapeutics reports Q2 net loss $10.1M, cash $43.5M; advances DM199 clinical programs

DiaMedica Therapeutics reported a Q2 2026 net loss of $10.1 million and ended the quarter with $43.5 million in cash, projecting a cash runway through 2027. The company is advancing its DM199 clinical programs, including positive Phase 2 results for late-onset preeclampsia, ongoing enrollment …

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics reported its Q2 2026 financial results and provided business updates, highlighting progress in its clinical trials for preeclampsia, fetal growth restriction (FGR), and acute ischemic stroke (AIS). The company announced the completion of enrollment for the first cohort of its Phase 2 …

DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient trigger

Earnings Call Insights: DiaMedica Therapeutics (DMAC) Q2 2026 MANAGEMENT VIEW * “Q2 was an important quarter for DiaMedica with progress across DM199 in early onset fetal growth restriction, preeclampsia and acute ischemic stroke,” said President, CEO & Director Dietrich Pauls, highlighting “enrollment has been …

HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC)

HC Wainwright has reaffirmed its "Buy" rating for DiaMedica Therapeutics (NASDAQ:DMAC) and maintained a $12 price target, indicating a potential 74.8% upside. The company recently reported a quarterly loss of $0.19 per share, exceeding analyst expectations. DiaMedica Therapeutics, a clinical-stage biopharmaceutical company, focuses on …

DiaMedica Therapeutics Q2 Earnings Call Highlights

DiaMedica Therapeutics provided updates on its Q2 progress, focusing on advancing DM199 for early-onset fetal growth restriction (FGR), preeclampsia, and acute ischemic stroke. The company completed enrollment for the first cohort of its Phase II FGR study and presented positive blood pressure reduction data …

Earnings call transcript: DiaMedica Q2 2026 loss matches forecast as trials advance

DiaMedica Therapeutics reported a Q2 2026 loss that matched Wall Street forecasts, with adjusted earnings of negative $0.19 per share and no revenue. The biotech company is advancing its clinical programs in preeclampsia, fetal growth restriction, and stroke, noting progress in all three areas. …

DiaMedica Therapeutics (DMAC) Reports Positive Interim Data, Market Pricing Reflects High Growth Expectations

DiaMedica Therapeutics (DMAC) announced positive interim results from its Phase 2 clinical trial for DM199 in preeclampsia treatment, highlighting its potential in various ischemic diseases. Despite being unprofitable and lacking sales, the company's high Price-to-Sales ratio and strong momentum reflect significant market expectations for …

DiaMedica Q2 net loss widens to $10.1M as DM199 shows clinical promise

DiaMedica Therapeutics Inc. reported a Q2 2026 net loss of $10.1 million, an increase from $7.7 million in the prior year, primarily due to a 41% rise in R&D expenses. Despite the widening loss, the company made significant clinical progress with its lead candidate …

DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly earnings per share (EPS) of negative $0.19, exceeding analyst estimates by $0.01. Despite this beat, shares fell 1.5% to $6.65, and the company's market capitalization stands at approximately $358.3 million, significantly below its 52-week high. Analyst sentiment is a …

DiaMedica Therapeutics (NASDAQ: DMAC) increases R&D spend and loss in Q2 2026

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported a wider net loss of $20.2 million for the first half of 2026, compared to $15.4 million a year earlier, primarily due to increased research and development (R&D) spending. R&D expenses rose to $16.1 million as the company …

DiaMedica Therapeutics Inc (DMAC) Stock News Today

(DMAC) Price Dynamics and Execution-Aware Positioning

This article provides an AI-driven analysis of Diamedica Therapeutics Inc. (NASDAQ: DMAC) focusing on price dynamics and execution-aware positioning. It highlights divergent sentiment readings, resistance testing, and an exceptional risk-reward short setup. The report outlines three institutional trading strategies (Position, Momentum Breakout, and Risk …

DMAC: Q2 2026 results and business update set for August 11, focusing on ischemic disease therapies

DiaMedica Therapeutics (DMAC) will release its Q2 2026 financial results and provide a business update on August 11, 2026, accompanied by a live conference call. The company is currently focused on developing innovative treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke. This …

DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced it will release its second quarter 2026 financial results after market close on Monday, August 10th. The company will host a conference call on Tuesday, August 11th, at 8:00 AM Eastern Time to discuss the results and provide …

DiaMedica Therapeutics (DMAC) Expected to Post Earnings on Tuesday

DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential

1 Main Capital highlighted DiaMedica Therapeutics (DMAC) in its Q2 2026 investor letter, noting the company's development of DM199 for ischemic diseases. Despite the fund's avoidance of AI semiconductor stocks due to valuation concerns, it holds an opportunistic position in DMAC, which has shown …

DiaMedica Therapeutics Inc (DMAC) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of DiaMedica Therapeutics Inc's (DMAC) financial health, noting its weak financial status and low operating efficiency with a score of 5.46. The company ranks 352 out of 384 in the Biotechnology & Medical Research industry. Several key financial metrics …

DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 1.5% - Should You Sell?

DiaMedica Therapeutics Inc (DMAC) Institutional Confidence

DiaMedica Therapeutics Inc (DMAC) has an institutional shareholding score of 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently increased by 33.63% quarter-over-quarter to 34.71%. Bill Nygren | OAKMX is the largest institutional shareholder, …

DMAC|DiaMedica Therapeutics Inc|Price:6.720|Chg%:-0.015

This article provides a comprehensive stock analysis of DiaMedica Therapeutics Inc (DMAC), highlighting its weak fundamentals but high growth potential. The stock is considered fairly valued with strong institutional ownership and multiple "Buy" ratings from analysts. The company's lead candidate, DM199, is in clinical …

DiaMedica Therapeutics Inc. Revenue Breakdown – NASDAQ:DMAC

DiaMedica Therapeutics Inc (DMAC) Income Statement

This article presents the income statement for DiaMedica Therapeutics Inc (DMAC), offering both quarterly and annual financial data. It details various financial metrics such as total revenue, operating expenses, R&D expenses, depreciation, operating profit, and net income, allowing investors to analyze the company's performance …

DiaMedica Therapeutics Inc (DMAC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of DiaMedica Therapeutics Inc's (DMAC) shareholder structure, including major individual and institutional holders. It lists the top shareholders by proportion, categorizes shareholders by type (e.g., corporation, private equity, individual investor), and shows institutional shareholding trends over several quarters. …

DiaMedica Therapeutics Inc (DMAC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of DiaMedica Therapeutics Inc (DMAC) including its current stock price and market capitalization. It specifically focuses on the company's dividend history, noting that no dividends have been distributed over the past five years. The page also offers sections for …

DiaMedica Therapeutics Market Sentiment

This article provides an overview of market sentiment for DiaMedica Therapeutics (DMAC), including analyst consensus, short interest, options flow, and insider activity. It highlights that analysts have a "Buy" consensus with an average price target significantly above the current stock price, while short interest …

DiaMedica Therapeutics Inc (DMAC) Cash Flow

This article provides a detailed cash flow statement for DiaMedica Therapeutics Inc (DMAC), covering quarterly data from FY2012Q1 to FY2026Q1, for Operating, Investing, and Financing activities. It also includes key financial metrics like Net Income, Capital Expenditures, and Free Cash Flow, along with definitions …

DiaMedica Therapeutics Inc (DMAC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of DiaMedica Therapeutics Inc (DMAC), noting its current valuation score of 7.24 and ranking in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio, while indicating that P/B and P/CF data are not yet disclosed. …

DMAC|DiaMedica Therapeutics Inc|Price:6.735|Chg%:-0.085

DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biopharmaceutical company focusing on treatments for preeclampsia and acute ischemic stroke with its lead candidate, DM199. The company's stock is currently priced at $6.735, showing a -1.25% change, and analysts have a "Buy" rating with a target …

Price to book forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC

This article provides the "Price to book forward" financial metric for DiaMedica Therapeutics Inc. (NASDAQ: DMAC). It also indicates that this information is "Made by humans" and clarifies the data sources and copyright information from TradingView.

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 17, 2026

DiaMedica Therapeutics Inc. announced inducement grants on July 17, 2026, awarding options to purchase 160,000 shares of common stock to a newly hired non-executive employee. These options, granted as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4), have an exercise price of …

New DiaMedica hire gets 160,000 stock options at $7.64

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it granted options to a newly hired non-executive employee to purchase 160,000 shares of common stock. The stock options, with an exercise price of $7.64 per share, were a material inducement for their employment, complying with Nasdaq …